Biological Therapies in the Treatment of Cancer—Update and New Directions

Advances in the development of personalized neoantigen-based therapeutic cancer vaccines

(2021) Eryn Blass et al.   Nature Reviews Clinical Oncology

Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma

(2021) Agrima Mian et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Vaccine Therapies for Cancer: Then and Now

(2021) Michael A. Morse et al.   Targeted Oncology

From antibodies to living drugs: Quo vadis cancer immunotherapy?

(2021) Árpád Szöőr et al.   Biologia Futura

Novel Pan-Pim Kinase Inhibitors With Imidazopyridazine and Thiazolidinedione Structure Exert Potent Antitumor Activities

(2021) Yuichi Sawaguchi et al.   Frontiers in Pharmacology

Indoleamine 2,3-Dioxygenase 1 Inhibitor-Loaded Nanosheets Enhance CAR-T Cell Function in Esophageal Squamous Cell Carcinoma

(2021) Jingwen Shao et al.   Frontiers in Immunology

Finding inhibitors for PCSK9 using computational methods

(2021) Rida Zainab et al.   PLoS One

Safety and efficacy of blinatumomab: a real world data

(2020) Arie Apel et al.   ANNALS OF HEMATOLOGY

Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.

(2020) Robert Connor Chick et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC).

(2020) Horst-Dieter Hummel et al.   JOURNAL OF CLINICAL ONCOLOGY

Recent advances of oncolytic virus in cancer therapy

(2020) Moumita Mondal et al.   Human Vaccines & Immunotherapeutics

Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies

(2020) Michael Lim et al.   Pharmaceutics

A humanized Lym-1 CAR with novel DAP10/DAP12 signaling domains demonstrates reduced tonic signaling and increased anti-tumor activity in B Cell Lymphoma models

(2020) Long Zheng et al.   CLINICAL CANCER RESEARCH

Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).

(2020) Keunchil Park et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.

(2020) Erika Paige Hamilton et al.   JOURNAL OF CLINICAL ONCOLOGY

Nanostructured toxins for the selective destruction of drug-resistant human CXCR4+ colorectal cancer stem cells

(2020) Naroa Serna et al.   JOURNAL OF CONTROLLED RELEASE

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

(2020) Hanren Dai et al.   Journal of Hematology & Oncology

Strong vaccine responses during chemotherapy are associated with prolonged cancer survival

(2020) Cornelis J. M. Melief et al.   Science Translational Medicine

Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours

(2020) Elżbieta Chruściel et al.   Cancers

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

(2020) Caron A. Jacobson et al.   JOURNAL OF CLINICAL ONCOLOGY

A conformation-specific ON-switch for controlling CAR T cells with an orally available drug

(2020) Charlotte U. Zajc et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up

(2020) Joost H van den Berg et al.   Journal for ImmunoTherapy of Cancer

Leukemia Stem Cell Release From the Stem Cell Niche to Treat Acute Myeloid Leukemia

(2020) Alicia Villatoro et al.   Frontiers in Cell and Developmental Biology

Progress in Neoantigen Targeted Cancer Immunotherapies

(2020) Xue-Jiao Han et al.   Frontiers in Cell and Developmental Biology

Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses

(2020) Claire Gorby et al.   Science Signaling

Immunotherapy for early breast cancer: too soon, too superficial, or just right?

(2020) M.A. Franzoi et al.   ANNALS OF ONCOLOGY

ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity

(2020) Brian B Haines et al.   Cancer Immunology Research

Turning the corner on therapeutic cancer vaccines

(2019) Robert E. Hollingsworth et al.   npj Vaccines

Turning “Cold” Into “Hot” Tumors—Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers

(2019) Lisa Sevenich   Frontiers in Oncology

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

(2019) Timothy F. Cloughesy et al.   NATURE MEDICINE

A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia

(2019) Ronja Bjørnstad et al.   MOLECULAR CANCER THERAPEUTICS

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

(2019) James L. Gulley et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer

(2019) Marie Christine Wulff Westergaard et al.   BRITISH JOURNAL OF CANCER

Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells

(2019) Rein Verbeke et al.   ACS Nano

CXCL12/CXCR4 pathway orchestrates CSC-like properties by CAF recruited tumor associated macrophage in OSCC

(2019) Xing Li et al.   EXPERIMENTAL CELL RESEARCH

Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy

(2019) J. Patrick Murphy et al.   JOURNAL OF PROTEOME RESEARCH

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy

(2019) Stefan Stoiber et al.   Cells

Finding Neo (antigens, that is)

(2019) Johanna Olweus et al.   BLOOD

Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling

(2019) Junfeng Bi et al.   Cell Metabolism

An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment

(2019) Yi Wang et al.   Frontiers in Immunology

Peptides as cancer vaccines

(2019) Marta Calvo Tardón et al.   CURRENT OPINION IN PHARMACOLOGY

Leukemia stem cells promote chemoresistance by inducing downregulation of lumican in mesenchymal stem cells

(2019) Zhen Yu et al.   Oncology Letters

Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade

(2019) Lee P. Richman et al.   Cell Systems

Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy

(2019) Zuan-Fu Lim et al.   Journal of Hematology & Oncology

Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display

(2019) Stina L. Wickström et al.   Frontiers in Immunology

Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances

(2019) Meijun Zheng et al.   Molecular Therapy-Oncolytics

Nanoparticle cancer vaccines: design considerations and recent advances

(2019) Jingjing Liu et al.   Asian Journal of Pharmaceutical Sciences

Role of Matrix Metalloproteinases in Angiogenesis and Cancer

(2019) Saray Quintero-Fabián et al.   Frontiers in Oncology

A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia

(2018) David Martínez-Cuadrón et al.   ANNALS OF HEMATOLOGY

Stromal cell-derived factor-1 (CXCL12) activates integrins by direct binding to an allosteric ligand-binding site (site 2) of integrins without CXCR4

(2018) Masaaki Fujita et al.   BIOCHEMICAL JOURNAL

hsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survival

(2018) Francesca Pellicano et al.   BLOOD

Oncolytic viruses and immunity

(2018) Shyambabu Chaurasiya et al.   CURRENT OPINION IN IMMUNOLOGY

Current challenges for cancer vaccine adjuvant development

(2018) William S. Bowen et al.   Expert Review of Vaccines

A Rapamycin-Activated Caspase 9-Based Suicide Gene

(2018) Maria Stavrou et al.   MOLECULAR THERAPY

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor endothelial marker 8 promotes cancer progression and metastasis

(2018) Anette M. Høye et al.   Oncotarget

Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies

(2018) Shangjun Sun et al.   Journal of Immunology Research

A comprehensive review of protein kinase inhibitors for cancer therapy

(2018) Radhamani Kannaiyan et al.   Expert Review of Anticancer Therapy

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials

(2018) Jonathan G. Pol et al.   OncoImmunology

664PPhase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)

(2018) M Alsina et al.   ANNALS OF ONCOLOGY

FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

(2018) Maura C. O’Leary et al.   CLINICAL CANCER RESEARCH

Multipotent mesenchymal stromal cells play critical roles in hepatocellular carcinoma initiation, progression and therapy

(2018) Zeli Yin et al.   Molecular Cancer

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

(2018) Derin B. Keskin et al.   NATURE

Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors

(2018) Jun Tang et al.   NATURE REVIEWS DRUG DISCOVERY

Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology

(2018) Keisuke Watanabe et al.   Frontiers in Immunology

Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma

(2017) Wei Xiao et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells

(2017) Iulia Diaconu et al.   MOLECULAR THERAPY

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation

(2017) Sivan Seliktar-Ofir et al.   Frontiers in Immunology

Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors

(2017) Alicia M. Waters et al.   Human Gene Therapy Clinical Development

Applications of Phosphate Modification and Labeling to Study (m)RNA Caps

(2017) Marcin Warminski et al.   Topics in Current Chemistry

Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion

(2017) Julia V. Cockle et al.   Molecular Therapy-Oncolytics

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

(2016) Robert H. I. Andtbacka et al.   ANNALS OF SURGICAL ONCOLOGY

Immune checkpoint blockade: Releasing the brake towards hematological malignancies

(2016) Yi Xia et al.   BLOOD REVIEWS

Osimertinib for the Treatment of Metastatic EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer

(2016) Sean Khozin et al.   CLINICAL CANCER RESEARCH

CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia

(2016) Nathan Singh et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

(2016) Igor Puzanov et al.   JOURNAL OF CLINICAL ONCOLOGY

Growth differentiation factor 15 contributes to cancer-associated fibroblasts-mediated chemo-protection of AML cells

(2016) Yuanmei Zhai et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Neoantigen landscape dynamics during human melanoma–T cell interactions

(2016) Els M. E. Verdegaal et al.   NATURE

Cancer immunotherapy targeting neoantigens

(2016) Yong-Chen Lu et al.   SEMINARS IN IMMUNOLOGY

Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma

(2016) Daxa M. Patel et al.   Human Gene Therapy Clinical Development

Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies

(2016) Marco Ruella et al.   Computational and Structural Biotechnology Journal

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

(2015) Soranobu Ninomiya et al.   BLOOD

Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)

(2015) Xiao-jun Lin et al.   BMC CANCER

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

(2015) Zeguo Zhao et al.   CANCER CELL

Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells

(2015) Mario Dicato et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

(2015) Cornelia L Trimble et al.   LANCET

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes

(2015) Ignazio Caruana et al.   NATURE MEDICINE

The pharmacology of second-generation chimeric antigen receptors

(2015) Sjoukje J. C. van der Stegen et al.   NATURE REVIEWS DRUG DISCOVERY

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis

(2015) Tengfei Zhang et al.   Oncotarget

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumorsin vivo

(2015) Mythili Koneru et al.   OncoImmunology

Re-engineering Vesicular Stomatitis Virus to Abrogate Neurotoxicity, Circumvent Humoral Immunity, and Enhance Oncolytic Potency

(2014) A. Muik et al.   CANCER RESEARCH

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

(2014) E. Tran et al.   SCIENCE

The Effect of Molecular Weight, PK, and Valency on Tumor Biodistribution and Efficacy of Antibody-Based Drugs

(2014) Ruth Muchekehu et al.   Translational Oncology

Improving the safety of cell therapy products by suicide gene transfer

(2014) Benjamin S. Jones et al.   Frontiers in Pharmacology

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

(2014) Howard L Kaufman et al.   Journal for ImmunoTherapy of Cancer

Activation of Dendritic Cells by the Novel Toll-Like Receptor 3 Agonist RGC100

(2013) Kai Naumann et al.   Clinical & Developmental Immunology

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

(2013) Richard A. Morgan et al.   JOURNAL OF IMMUNOTHERAPY

At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy

(2013) Margaret K. Callahan et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Macrophage biology in development, homeostasis and disease

(2013) Thomas A. Wynn et al.   NATURE

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multilevel pharmacological manipulation of adenosine–prostaglandin E2/cAMP nexus in the tumor microenvironment: A ‘two hit’ therapeutic opportunity

(2013) Muzammal Hussain et al.   PHARMACOLOGICAL RESEARCH

Expression of pim-1 in Tumors, Tumor Stroma and Tumor-Adjacent Mucosa Co-Determines the Prognosis of Colon Cancer Patients

(2013) Yong-hai Peng et al.   PLoS One

Function of Jam-B/Jam-C Interaction in Homing and Mobilization of Human and Mouse Hematopoietic Stem and Progenitor Cells

(2013) Marie-Laure Arcangeli et al.   STEM CELLS

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

(2012) G. L. Uy et al.   BLOOD

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

(2012) M. Klinger et al.   BLOOD

Fibroblast activation protein

(2012) Rui Liu et al.   CANCER BIOLOGY & THERAPY

Building tolerance by dismantling synapses: inhibitory receptor signaling in natural killer cells

(2012) Morgan Huse et al.   IMMUNOLOGICAL REVIEWS

Antitumor activities of PSMA×CD3 diabodies by redirected T-cell lysis of prostate cancer cells

(2012) Volker Baum et al.   Immunotherapy

Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice

(2012) Marc Mueller et al.   JOURNAL OF CONTROLLED RELEASE

Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling

(2012) Simone Diermeier-Daucher et al.   mAbs

Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

(2012) M. K. Gleason et al.   MOLECULAR CANCER THERAPEUTICS

Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance

(2012) Ingrid G Winkler et al.   NATURE MEDICINE

A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma

(2011) Lutz Eric et al.   ANNALS OF SURGERY

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

(2011) P. A. Moore et al.   BLOOD

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo

(2010) A N Kuhn et al.   GENE THERAPY

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Bispecific antibodies for cancer therapy

(2010) Patrick Chames et al.   mAbs

Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody

(2010) Kerstin Fortmüller et al.   PROSTATE

Therapeutic antibodies: successes, limitations and hopes for the future

(2009) Patrick Chames et al.   BRITISH JOURNAL OF PHARMACOLOGY

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

(2009) Celestia S. Higano et al.   CANCER

The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2

(2009) M. Jager et al.   CANCER RESEARCH

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

Cancer associated fibroblasts (CAFs) in tumor microenvironment

(2009) Fei Xing   Frontiers in Bioscience-Landmark

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis

(2009) Michael A Strohlein et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Unknown

(2009) Nanhai Chen et al.   MOLECULAR MEDICINE

Synthesis and characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to eIF4E and are resistant to the decapping pyrophosphatase DcpS

(2008) J. Kowalska et al.   RNA

Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells

(2008) Angela Colmone et al.   SCIENCE